Literature DB >> 26138264

Thymic carcinoma patients with myasthenia gravis exhibit better prognoses.

Wenya Li1, Zhifeng Miao2, Xudong Liu3, Qigang Zhang1, Lei Sun1, Peiwen Li1, Wenke Liu1, Lin Zhang4.   

Abstract

BACKGROUND: Thymic carcinoma is an aggressive mediastinal neoplasm with a poor prognosis, but the factors that contribute to its prognosis are not completely understood. Myasthenia gravis (MG) can coexist with thymic carcinoma with low incidence, but the effect MG has on thymic carcinoma prognosis is unknown. Here, we investigated the prognostic factors of thymic carcinoma and the influence of MG on patients with this disease.
METHODS: Between January 1996 and December 2012, 49 patients were diagnosed with thymic carcinoma and surgically treated at our institution. Clinical data and survival information were recorded and systematically reviewed. Kaplan-Meier survival curves were generated, and independent prognostic factors were identified by Cox's proportional hazard model.
RESULTS: Complete resection was achieved in 30 patients (61.2 %), and incomplete resection was performed on the other 19 patients (38.8 %). Six of the 49 patients with thymic carcinoma also presented with MG (12.2 %). Interestingly, these 6 patients exhibited much better prognoses when compared to the other 43 patients. Patients with MG also had significantly smaller tumors (P = 0.045), earlier Masaoka stage (P = 0.048), and higher complete resection rates (P = 0.042). However, multivariate analysis demonstrated that complete resection was the only independent predictor for overall survival (OS) (P < 0.001).
CONCLUSIONS: The OS of patients with thymic carcinoma depends on complete resection, but patients with MG also demonstrate improved prognoses. MG patients have higher rates of complete surgical resection, which may account for their better prognoses. Patients with MG have unique features that may aid in the clinical management of these patients.

Entities:  

Keywords:  Complete resection; Myasthenia gravis; Prognosis; Thymic carcinoma

Mesh:

Year:  2015        PMID: 26138264     DOI: 10.1007/s10147-015-0862-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  28 in total

1.  Standard outcome measures for thymic malignancies.

Authors:  James Huang; Frank C Detterbeck; Zuoheng Wang; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

2.  Importance of lymph node dissection in thymic carcinoma.

Authors:  In Kyu Park; Young Tae Kim; Jae Hyun Jeon; Hye-Seon Kim; Yoohwa Hwang; Yong Won Seong; Chang Hyun Kang; Joo Hyun Kim
Journal:  Ann Thorac Surg       Date:  2013-06-24       Impact factor: 4.330

3.  Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study.

Authors:  Ankit Modh; Andreas Rimner; Pamela K Allen; Brad Greenfield; Edith M Marom; David Rice; James Huang; Kenneth E Rosenzweig; Ritsuko Komaki; Daniel R Gomez
Journal:  Am J Clin Oncol       Date:  2016-04       Impact factor: 2.339

4.  Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma.

Authors:  Yasuko Hosaka; Masanori Tsuchida; Shin-ichi Toyabe; Hajime Umezu; Tadaaki Eimoto; Jun-ichi Hayashi
Journal:  Ann Thorac Surg       Date:  2010-03       Impact factor: 4.330

5.  Thymic carcinoma: current staging does not predict prognosis.

Authors:  D Blumberg; M E Burt; M S Bains; R J Downey; N Martini; V Rusch; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1998-02       Impact factor: 5.209

Review 6.  Thymoma and thymic carcinoma.

Authors:  Federico Venuta; Marco Anile; Daniele Diso; Domenico Vitolo; Erino A Rendina; Tiziano De Giacomo; Federico Francioni; Giorgio Furio Coloni
Journal:  Eur J Cardiothorac Surg       Date:  2009-07-16       Impact factor: 4.191

7.  Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.

Authors:  Kazuya Kondo; Yasumasa Monden
Journal:  Ann Thorac Surg       Date:  2003-09       Impact factor: 4.330

Review 8.  Diagnostic and clinical classification of autoimmune myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Mélinée Frenkian-Cuvelier; Bruno Eymard
Journal:  J Autoimmun       Date:  2014-02-13       Impact factor: 7.094

Review 9.  Historical perspectives: The evolution of the thymic epithelial tumors staging system.

Authors:  Pier Luigi Filosso; Enrico Ruffini; Paolo Olivo Lausi; Marco Lucchi; Alberto Oliaro; Frank Detterbeck
Journal:  Lung Cancer       Date:  2013-10-15       Impact factor: 5.705

Review 10.  Myasthenia gravis.

Authors:  J Spillane; E Higham; D M Kullmann
Journal:  BMJ       Date:  2012-12-21
View more
  9 in total

1.  The Studies of Prognostic Factors and the Genetic Polymorphism of Methylenetetrahydrofolate Reductase C667T in Thymic Epithelial Tumors.

Authors:  Miaolong Yan; Jiayuan Wu; Min Xue; Juanfen Mo; Li Zheng; Jun Zhang; Zhenzhen Gao; Yi Bao
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

2.  Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Authors:  Sukhmani K Padda; Xiaopan Yao; Alberto Antonicelli; Jonathan W Riess; Yue Shang; Joseph B Shrager; Robert Korst; Frank Detterbeck; James Huang; Bryan M Burt; Heather A Wakelee; Sunil S Badve
Journal:  J Thorac Oncol       Date:  2017-11-27       Impact factor: 15.609

3.  Malignant thymoma with metastasis associated with paraneoplastic myasthenia gravis.

Authors:  Hourossadat Hashemi Jazi; David M Harmon; Tuan Tran; Claude Denham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

4.  Rare frequency of gene variation and survival analysis in thymic epithelial tumors.

Authors:  Zhengbo Song; Xinmin Yu; Yiping Zhang
Journal:  Onco Targets Ther       Date:  2016-10-14       Impact factor: 4.147

5.  Does Myasthenia Gravis Affect Long-Term Survival in Thymic Carcinomas? An ESTS Database Analysis.

Authors:  Filippo Lococo; Dania Nachira; Marco Chiappetta; Jessica Evangelista; Pierre Emmanuel Falcoz; Enrico Ruffini; Paul Van Schil; Marco Scarci; Jòzsef Furàk; Francesco Sollitto; Francesco Guerrera; Lorenzo Spaggiari; Clemens Aigner; Liverakou Evangelia; Andrea Billè; Bernhard Moser; Pascal Alexandre Thomas; Moishe Liberman; Souheil Boubia; Alessio Campisi; Luca Ampollini; Alper Toker; Attila Enyed; Luca Voltolini; Dirk Van Raemdonck; Stefano Margaritora
Journal:  Diagnostics (Basel)       Date:  2022-07-21

6.  Myasthenia gravis as a prognostic marker in patients with thymoma.

Authors:  Bernardo Cacho-Díaz; Karen Salmerón-Moreno; Nydia A Lorenzana-Mendoza; Julia Texcocano; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  Thymic Carcinomas and Second Malignancies: A Single-Center Review.

Authors:  Sunil S Badve; Rachel Dougherty; Michael Balatico; Kenneth A Kesler; Patrick Loehrer; Yesim Gökmen-Polar
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

8.  Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

Authors:  Hiroshi Shima; Hiroaki Ozasa; Takahiro Tsuji; Hitomi Ajimizu; Takashi Nomizo; Yoshitaka Yagi; Yuichi Sakamori; Hiroki Nagai; Sachiko Minamiguchi; Young Hak Kim; Michiaki Mishima
Journal:  Mol Clin Oncol       Date:  2016-03-07

9.  Influence of body mass index on postoperative complications after thymectomy in myasthenia gravis patients.

Authors:  Xu-Dong Liu; Ming-Rui Shao; Lei Sun; Lin Zhang; Xin-Shan Jia; Wen-Ya Li
Journal:  Oncotarget       Date:  2017-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.